Burn, Partial Thickness, Trauma-related Wound
Conditions
Brief summary
The objective of the study is to evaluate Procellera® , a novel FDA approved antimicrobial wound dressing in a prospective, randomized, controlled clinical study. The hypothesis is that when the dressing is moistened, the low electric field created by moisture-activated elemental silver and zinc electro-couple will prevent formation of biofilm in wounds or to disrupt existing biofilm.
Detailed description
The healing of traumatic wounds, to include burns, can be compromised by the presence of infection so efforts are made to prevent or diagnose infection early in order to mitigate the negative impact on healing. Electric stimulation has previously been shown to have both bacteriostatic and bactericidal effects in wounds. Until now, administering low intensity electric field/micro-current as a therapy to mitigate biofilm infection and to improve wound healing was not feasible. In this study the investigators will use Procellera® , a FDA approved fabric based wireless electroceutical dressing (WED) consisting of a silver-zinc electro-couple for the prevention of wound biofilm formation. The dressing generates a low electric field (\ 1V) upon activation by a moist environment, which mitigates biofilm formation and promotes wound healing. The objectives of the study are to evaluate the efficacy of a wireless electroceutical dressing to prevent the formation or disrupting existing biofilms. The investigators will conduct a prospective, randomized controlled clinical trial using the Procellera® dressing compared to the standard of care. Treatment sites will be randomized to either receiving Procellera® or the standard of care treatment. Objective measurements and assessments will be completed during subject follow-up visits for up to one month post treatment. This includes biopsies to calculate bacterial load by assessing colony forming unit (CFU) count and bacterial film visualization using scanning electron microscopy, histology, clinical assessment of infection, Transepidermal Water Loss (TEWL) and wound photography.
Interventions
DEVICEProcellera®
Application of Procellera® dressing.
OTHERStandard of Care
Application of standard of care dressings as prescribed.
Sponsors
Indiana University
The Metis Foundation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
Biopsies obtained will be sent to Indiana University for blinded processing and analysis.
Intervention model description
Participants will have two wound sites that will be randomized to receive either the standard of care treatment or the Procellera® (electroceutical) dressing.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 18-65 years of age * Willing and able to provide informed consent * Participant has acute partial-thickness or full-thickness wounds caused by trauma or partial-thickness burns that are ≥ 300 cm2 in size in one contiguous area or two separate wound sites ≥ 150 cm2 each
Exclusion criteria
* Pregnancy * Prisoner * Active malignancy or immunosuppressive therapy * Current systemic steroid use * Known allergy or sensitivity to silver or zinc * Participant's proposed study wound site has any of the following conditions: * Location is on the hands, face or feet * Full-thickness burn wounds * Exposure of visceral organs * Exposure of hardware or prosthetic exposure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Presence of biofilm | Day seven | Presence of biofilm will be assessed by obtaining a wound biopsy and analyzing with Scanning Electron Microscopy. |
| Rate of eradication of biofilm production | Day 7 | Presence of biofilm will be assessed by obtaining a wound biopsy and analyzing with Scanning Electron Microscopy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of healing | Day 30 | Quality of healing post-epithelialization as measured by the validated Patient Observer Scar Assessment Scale (POSAS) |
| Incidence of infection | Day 0-30 | Wounds will be assessed for the presence of clinical evidence indicating infection. |
| Incidence of adverse events | Day 0-30 | The incidence of adverse events will be reported to assess safety. |
| Quantitative bacterial load calculation | Day 7 | Quantitative bacterial load will be assessed by obtaining a wound biopsy and analyzed by performing colony forming unit counts |
| Percent epithelialization | Day 7 | The percentage of epitheliazation will be assessed utilizing clinical assessments and the Silhouette Star wound camera. |
Countries
United States
Outcome results
None listed